

Statins Impair Glucose Uptake in Tumor Cells¹

Agata Malenda*, Anna Skrobanska*,
Tadeusz Issat*, Magdalena Winiarska*,
Jacek Bil*, Bozenna Oleszczak[†], Maciej Sinski[‡],
Małgorzata Firczuk*, Janusz M. Bujnicki^{§,¶},
Justyna Chlebowska*, Adam D. Staruch*,
Eliza Glodkowska-Mrowka*, Jolanta Kunikowska[#],
Leszek Krolicki[#], Leszek Szablewski[†],
Zbigniew Gaciong[‡], Katarzyna Koziak**,
Marek Jakobisiak*, Jakub Golab*,
and Dominika A. Nowis*

*Department of Immunology, Center of Biostructure Research, Medical University of Warsaw, Warsaw, Poland;
†Center of Biostructure Research, Medical University of Warsaw, Warsaw, Poland;
†Department of Internal Diseases, Hypertension and Vascular Disease, Medical University of Warsaw, Warsaw, Poland;
\$\frac{1}{2}\text{Laboratory of Bioinformatics and Protein Engineering, International Institute of Molecular and Cell Biology in Warsaw, Warsaw, Poland;
*Bioinformatics Laboratory, Institute of Molecular Biology and Biotechnology, Adam Mickiewicz University, Poznan, Poland;
#Nuclear Medicine Department, Medical University of Warsaw, Warsaw, Warsaw, Poland;
**Department of General and Nutritional Biochemistry, Medical University of Warsaw, Warsaw, Poland;
**Polish Academy of Sciences, Department 3, Warsaw, Poland

Abstract

Statins, HMG-CoA reductase inhibitors, are used in the prevention and treatment of cardiovascular diseases owing to their lipid-lowering effects. Previous studies revealed that, by modulating membrane cholesterol content, statins could induce conformational changes in cluster of differentiation 20 (CD20) tetraspanin. The aim of the presented study was to investigate the influence of statins on glucose transporter 1 (GLUT1)—mediated glucose uptake in tumor cells. We observed a significant concentration- and time-dependent decrease in glucose analogs' uptake in several tumor cell lines incubated with statins. This effect was reversible with restitution of cholesterol synthesis pathway with mevalonic acid as well as with supplementation of plasma membrane with exogenous cholesterol.

Abbreviations: 2-DOG, 2-deoxyglucose; 6-NBDG, 6-(*N*-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-6-deoxyglucose; CD, cluster of differentiation; CRAC, cholesterol recognition/interaction amino acid consensus; ¹⁸F-FDG, [¹⁸F]fluoro-2-deoxyglucose; FPP, farnesyl pyrophosphate; GLUT, glucose transporter; HA, hemagglutinin; MA, mevalonic acid; MβCD, methyl-β-cyclodextrin; PBMC, peripheral blood mononuclear cell; PET/CT, positron emission tomography/computed tomography; SUV, standardized uptake value Address all correspondence to: Dominika A. Nowis, MD, PhD, Department of Immunology, Center of Biostructure Research, The Medical University of Warsaw, 1a Banacha Str., F Bldg, 02-097 Warsaw, Poland. E-mail: dominika.nowis@wum.edu.pl

¹J.G., A.M., and D.N. are recipients of the Mistrz Award from the Foundation for Polish Science. J.G., M.W., and M.F. are members of TEAM Programme co-financed by the Foundation for Polish Science and the EU European Regional Development Fund. The research was supported by grants 1M19/NM1 (to A.M.), 1M19/NM6 (to A.M.), and 1W13/W1/10 (to L.K.) from the Medical University of Warsaw, N N402 365438 (to J.G.), N N405 302836 (to M.J.) from Polish Ministry of Science, the European Union within European Regional Development Fund through Innovative Economy grant POIG.01.01.02-00-008/08 (to J.G.) as well as by grant N R13 0094 06 (to K.K.) from The National Centre for Research and Development. The work carried out by J.M.B. (modeling of GLUT1) was supported by the 7th Framework Programme of the European Commission (EC FP7, grant HEALTHPROT, contract number 229676). None of these organizations had any influence neither on the course of the studies nor on the preparation of the article. Received 26 February 2012; Revised 22 March 2012; Accepted 22 March 2012

Statins did not change overall GLUT1 expression at neither transcriptional nor protein levels. An exploratory clinical trial revealed that statin treatment decreased glucose uptake in peripheral blood leukocytes and lowered ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) uptake by tumor masses in a mantle cell lymphoma patient. A bioinformatics analysis was used to predict the structure of human GLUT1 and to identify putative cholesterol-binding motifs in its juxtamembrane fragment. Altogether, the influence of statins on glucose uptake seems to be of clinical significance. By inhibiting ¹⁸F-FDG uptake, statins can negatively affect the sensitivity of positron emission tomography, a diagnostic procedure frequently used in oncology.

Neoplasia (2012) 14, 311-323

Introduction

Owing to the deregulated blood supply, rapidly growing tumor cells suffer from lack of oxygen and nutrients. An increased glucose metabolism seems to be an important mechanism of tumor cells adapting to hypoxia. Intriguingly, transformed cells tend to use anaerobic glycolysis as their major energy supply even under normoxic conditions such as during cell culture. Although glycolysis is less efficient in generating ATP than oxidative phosphorylation (tricarboxylic acid cycle), it is much faster and provides substrates to the synthesis of amino acids, nucleotides, and fatty acids as well as reduces equivalents to minimize toxic effects of reactive oxygen species [1,2]. The shift in ATP generation from oxidative phosphorylation to glycolysis even under normal oxygen conditions is called the Warburg effect. It seems that the first regulatory step in glycolysis, that is, the increased glucose uptake, is the biologic basis for the diagnostic procedure of [18F] fluoro-2-deoxyglucose positron emission tomography (FDG PET) [3,4]. Although various mechanisms have been proposed to explain increased FDG uptake in growing tumors, a facilitative glucose transport by glucose transporters (GLUTs) seems to be the most important [5-7]. GLUT family includes 14 isoforms sharing common structural features including 12 transmembrane domains with both amino- and carboxy-terminal ends localized in the cytoplasm [8]. GLUT1 is frequently upregulated in tumor cells, which probably facilitates tumor growth beyond the size limited by their glycolytic capacity [9]. A number of studies indicate that increased GLUT1 expression correlates with higher tumor ¹⁸F-FDG uptake [10–12].

We have previously demonstrated that statins, which are the 3hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, can induce conformational changes in CD20 molecules. This results in impaired binding of anti-CD20 monoclonal antibodies and diminished ability to trigger complement-dependent cytotoxicity [13]. These effects turned out to be strictly cholesterol dependent because exogenous cholesterol could rapidly reverse the effects of statins. Atomic force microscopy, limited proteolysis, and functional data indicated that statins induced cholesterol-dependent conformational changes in CD20 tetraspanin. We hypothesized that statins could also induce conformational changes in other proteins with multiple membrane-spanning domains. Such possibility is also supported by a number of observations indicating that statins or membrane cholesterol depletion impairs the function of other proteins with multiple membrane-spanning domains including P-glycoprotein [14], P2X1-4 ATP receptors [15], voltage-gated chloride channel [16], G-protein-coupled cholecystokinin [17], or serotonin receptors [18]. Modeling of the serotonin_{1A} receptor revealed that, in the presence of cholesterol, the receptor acquires a more compact structure, and its ligands exhibit higher binding energies when docked to the receptor in the presence of cholesterol [19]. A recent study that used small-angle neutron scattering revealed that cholesterol-rich micellar nanostructures determine transmembrane protein (GPCR) activity and that successful reconstitution of the receptor is dependent on cholesterol-protein interactions [20]. Moreover, cholesterol-binding motifs have recently been characterized in acetylcholine receptors, which contain five transmembrane domains [21]. Therefore, we decided to investigate the influence of statins on the glucose transport into tumor cells, which frequently overexpress GLUT proteins and require efficient glucose uptake for their increased metabolic demands.

Materials and Methods

Cell Culture

Human Burkitt lymphoma (Daudi, Raji, Ramos), human follicular lymphoma (DoHH2), human colon adenocarcinoma (LoVo), and human embryonic kidney (HEK293T) cell lines were purchased from the American Tissue Culture Collection (Manassas, VA). Cells (Daudi, Raji, Ramos, DoHH2, and HEK293T) were cultured in RPMI 1640 or Dulbecco modified Eagle medium/F-12 medium (LoVo) supplemented with 10% heat-inactivated fetal bovine serum, 100 μg/ml streptomycin, and 250 ng/ml amphotericin B (all from Invitrogen, Carlsbad, CA). Cells were cultured at 37°C in a fully humidified atmosphere of 5% CO₂ and were passaged approximately every other day.

Reagents

The following statins were used: atorvastatin (Pfizer Pharmaceuticals, Inc, Groton, CT), cerivastatin (Bayer Corp, West Haven, CT), fluvastatin (Novartis Pharma AG, Basel, Switzerland), lovastatin, and simvastatin (both from Merck, Sharp & Dohme Res. Lab., Rahway, NJ). Lovastatin and simvastatin were obtained in the inactive lactone form. They were converted to the active form by dissolving in ethanol, heating for 2 hours at 50°C in 0.1N NaOH and neutralizing with HCl. Distilled water was added to obtain the final stock concentration of 10 mM. Stock solution was aliquoted and stored frozen (–20°C). Mevalonic acid (MA), farnesyl pyrophosphate (FPP), methyl- β -cyclodextrin (M β CD), and water-soluble cholesterol were purchased from Sigma (St Louis, MO). Farnesyltransferase inhibitor L-744,832 was obtained from Merck KGaA (Darmstadt, Germany); 6-(*N*-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-6-deoxyglucose (6-NBDG) was from Invitrogen and was dissolved in dimethyl sulfoxide to

Download English Version:

https://daneshyari.com/en/article/2151506

Download Persian Version:

https://daneshyari.com/article/2151506

Daneshyari.com